Immix Biopharma (NASDAQ:IMMX) Stock Price Down 5.4% - What's Next?

Key Points

• Immix Biopharma shares fell 5.4% to $13.16 in mid-day trading, with volume down 84% from the average. The stock remains above its 50-day and 200-day moving averages.
• Analyst sentiment is broadly positive, with eight Buy ratings and one Sell rating. The stock has a “Moderate Buy” consensus and an average price target of $21.29, substantially above its recent trading price.
• The company reported a quarterly loss of $0.18 per share, missing expectations by $0.01, and analysts expect a full-year loss of $0.74 per share. Immix Biopharma is developing immuno-oncology therapies, including lead candidate IMX-110.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) fell 5.4% during mid-day trading on Tuesday . The stock traded as low as $12.75 and last traded at $13.16. 199,127 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 1,266,649 shares. The stock had previously closed at $13.91.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Bank of America assumed coverage on shares of Immix Biopharma in a research report on Thursday, June 18th. They set a "buy" rating and a $27.00 price target on the stock. Citigroup reiterated a "market outperform" rating on shares of Immix Biopharma in a research note on Friday, August 14th. Lifesci Capital began coverage on shares of Immix Biopharma in a research report on Wednesday, June 17th. They set an "outperform" rating and a $19.00 target price on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Immix Biopharma in a research report on Friday, July 17th. Finally, HC Wainwright upped their target price on Immix Biopharma from $20.00 to $25.00 and gave the company a "buy" rating in a report on Monday, August 10th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immix Biopharma presently has an average rating of "Moderate Buy" and an average price target of $21.29.

Immix Biopharma Trading Down 4.4%

The stock has a market capitalization of $951.48 million, a PE ratio of -15.15 and a beta of 0.20. The firm has a 50-day moving average price of $11.10 and a 200-day moving average price of $9.85.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). Sell-side analysts expect that Immix Biopharma, Inc. will post -0.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC increased its stake in shares of Immix Biopharma by 9.5% during the 1st quarter. Private Advisor Group LLC now owns 34,725 shares of the company's stock worth $316,000 after purchasing an additional 3,000 shares during the last quarter. Legal & General Group Plc purchased a new position in Immix Biopharma in the second quarter valued at approximately $41,000. Allworth Financial LP purchased a new position in Immix Biopharma in the fourth quarter valued at approximately $30,000. California State Teachers Retirement System bought a new position in Immix Biopharma during the second quarter valued at $566,000. Finally, Compass Financial Management LLC bought a new position in Immix Biopharma during the second quarter valued at $56,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Company Profile

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.